1. Home
  2. LXRX
  3. LXRX News

Latest Lexicon Pharmaceuticals Inc. (LXRX) News on November 17, 2024

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago
LXRX

GlobeNewswire

3 days ago

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...
LXRX

GuruFocus.com

4 days ago

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates
LXRX

Zacks

4 days ago

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates

LXRX

Associated Press Finance

5 days ago

Lexicon: Q3 Earnings Snapshot

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
LXRX

GlobeNewswire

5 days ago

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For
LXRX

GuruFocus.com

6 days ago

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
LXRX

GlobeNewswire

11 days ago

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

A diabetes drug, twice rejected, stumbles again — but its developer persists
LXRX

Pharma Voice

11 days ago

A diabetes drug, twice rejected, stumbles again — but its developer persists

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
LXRX

GlobeNewswire

12 days ago

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024
LXRX

GlobeNewswire

12 days ago

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss
LXRX

GlobeNewswire

13 days ago

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

LXRX

MT Newswires

16 days ago

Sector Update: Health Care Stocks Rise Late Afternoon

LXRX

MT Newswires

16 days ago

Top Midday Decliners

LXRX

MT Newswires

16 days ago

Lexicon Pharmaceuticals Says FDA Panel Opposes Zynquista for Type 1 Diabetes and Kidney Disease

LXRX

MT Newswires

16 days ago

Top Premarket Decliners

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
LXRX

GlobeNewswire

16 days ago

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting
LXRX

TipRanks

21 days ago

FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting

New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024
LXRX

GlobeNewswire

25 days ago

New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
LXRX

GlobeNewswire

a month ago

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe
LXRX

BioPharma Dive

a month ago

Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe

Lexicon partners Viatris for global expansion of sotagliflozin
LXRX

Pharmaceutical Technology

a month ago

Lexicon partners Viatris for global expansion of sotagliflozin

LXRX

MT Newswires

a month ago

Lexicon Pharmaceuticals to Get $25 Million From Viatris in Global Sotagliflozin Licensing Deal

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
LXRX

GlobeNewswire

a month ago

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
LXRX

PR Newswire

a month ago

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ...
LXRX

GuruFocus.com

a month ago

Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ...

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
LXRX

GlobeNewswire

2 months ago

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

LXRX

MT Newswires

2 months ago

Lexicon Pharmaceuticals COO Jeff Wade Steps Down

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
LXRX

GlobeNewswire

2 months ago

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
LXRX

GlobeNewswire

2 months ago

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences
LXRX

GlobeNewswire

2 months ago

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration
LXRX

GlobeNewswire

2 months ago

New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration

Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025?
LXRX

Insider Monkey

2 months ago

Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025?

Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
LXRX

Zacks

3 months ago

Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More

Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
LXRX

Zacks

3 months ago

Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista

Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD
LXRX

Pharmaceutical Technology

3 months ago

Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD

LXRX

MT Newswires

3 months ago

Lexicon Pharmaceuticals Says FDA to Hold Meeting in October to Review Zynquista for Type 1 Diabetes, CKD

Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
LXRX

GlobeNewswire

3 months ago

Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista

Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up
LXRX

Zacks

3 months ago

Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up

LXRX

MT Newswires

3 months ago

Correction: Lexicon Pharmaceuticals Plans Job Cuts as Part of Cost-Cutting Measures

LXRX

MT Newswires

3 months ago

Lexicon Pharmaceuticals Plans Job Cuts as Part of Cost-Cutting Measures

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
LXRX

GlobeNewswire

3 months ago

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio

Lilly opens R&D hub; Ovid and Lexicon lay off staff
LXRX

BioPharma Dive

3 months ago

Lilly opens R&D hub; Ovid and Lexicon lay off staff

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
LXRX

GlobeNewswire

3 months ago

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists

Lexicon Pharmaceuticals Insider Buyers Pleased With US$724k Return On Investment
LXRX

Simply Wall St.

3 months ago

Lexicon Pharmaceuticals Insider Buyers Pleased With US$724k Return On Investment

LXRX

MT Newswires

3 months ago

Lexicon Pharmaceuticals Files $200 Million Mixed Shelf

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates
LXRX

Zacks

4 months ago

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates

LXRX

Associated Press Finance

4 months ago

Lexicon: Q2 Earnings Snapshot

Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
LXRX

GlobeNewswire

4 months ago

Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
LXRX

GlobeNewswire

4 months ago

Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
LXRX

Zacks

4 months ago

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates

FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug
LXRX

Zacks

4 months ago

FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug

LXRX

MT Newswires

4 months ago

Update: FDA Sets Target Action Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin

LXRX

MT Newswires

4 months ago

FDA Sets PDUFA Goal Date for Lexicon Pharmaceuticals' NDA Resubmission for Sotagliflozin

Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission
LXRX

GlobeNewswire

4 months ago

Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure
LXRX

GlobeNewswire

4 months ago

New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure

Private equity firms account for 48% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while individual investors account for 33%
LXRX

Simply Wall St.

4 months ago

Private equity firms account for 48% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while individual investors account for 33%

Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?
LXRX

Zacks

4 months ago

Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?

LXRX

MT Newswires

4 months ago

Lexicon Pharmaceuticals Names Mike Exton CEO, Jeff Wade Operating Chief

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
LXRX

GlobeNewswire

4 months ago

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

LXRX

MT Newswires

5 months ago

Sector Update: Health Care Stocks Gain in Late Afternoon

LXRX

MT Newswires

5 months ago

Lexicon Pharmaceuticals Resubmits New Drug Application for Potential Type 1 Diabetes Therapy

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
LXRX

GlobeNewswire

5 months ago

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes

Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
LXRX

GlobeNewswire

5 months ago

Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
LXRX

GlobeNewswire

5 months ago

Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology

LXRX

MT Newswires

5 months ago

HC Wainwright Initiates Lexicon Pharmaceuticals With Buy Rating, $10 Price Target

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
LXRX

GlobeNewswire

5 months ago

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association

Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?
LXRX

Zacks

5 months ago

Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?

Lexicon Pharmaceuticals (NASDAQ:LXRX) adds US$51m to market cap in the past 7 days, though investors from five years ago are still down 69%
LXRX

Simply Wall St.

5 months ago

Lexicon Pharmaceuticals (NASDAQ:LXRX) adds US$51m to market cap in the past 7 days, though investors from five years ago are still down 69%

Italian energy company targets Britain for fleet of 20 mini-nukes
LXRX

The Telegraph

5 months ago

Italian energy company targets Britain for fleet of 20 mini-nukes

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
LXRX

Motley Fool

5 months ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Seoul resumes loudspeaker propaganda against North
LXRX

AFP

5 months ago

Seoul resumes loudspeaker propaganda against North

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss
LXRX

Simply Wall St.

5 months ago

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss

American Software Full Year 2024 Earnings: EPS Beats Expectations
LXRX

Simply Wall St.

5 months ago

American Software Full Year 2024 Earnings: EPS Beats Expectations

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns
LXRX

Simply Wall St.

5 months ago

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
LXRX

Simply Wall St.

5 months ago

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

3 Mistakes That Can Get Your Costco Membership Canceled
LXRX

Motley Fool

5 months ago

3 Mistakes That Can Get Your Costco Membership Canceled

Lexicon selects Medidata to advance Phase IIb non-opioid pain drug trial
LXRX

Clinical Trials Arena

6 months ago

Lexicon selects Medidata to advance Phase IIb non-opioid pain drug trial

Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
LXRX

GlobeNewswire

6 months ago

Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024

LXRX

MT Newswires

6 months ago

Lexicon Pharmaceuticals Says Post Hoc Analysis of Infepa Trial Showed Decreased Heart Failure Risk; Shares Gain Pre-Bell

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
LXRX

GlobeNewswire

6 months ago

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
LXRX

GlobeNewswire

6 months ago

Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript
LXRX

Insider Monkey

6 months ago

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript

LXRX

Thomson Reuters StreetEvents

6 months ago

Q1 2024 Lexicon Pharmaceuticals Inc Earnings Call

LXRX

GuruFocus.com

6 months ago

Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
LXRX

Zacks

6 months ago

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates

Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ...
LXRX

GuruFocus.com

6 months ago

Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ...

LXRX

Associated Press Finance

6 months ago

Lexicon: Q1 Earnings Snapshot

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
LXRX

GlobeNewswire

6 months ago

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

LXRX

MT Newswires

7 months ago

Lexicon Pharmaceuticals' Chief Executive Lonnel Coats to Retire

Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
LXRX

GlobeNewswire

7 months ago

Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals

Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
LXRX

GlobeNewswire

7 months ago

Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024

Lexicon Pharmaceuticals to Host 2024 Investor Day
LXRX

GlobeNewswire

7 months ago

Lexicon Pharmaceuticals to Host 2024 Investor Day

All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy
LXRX

Zacks

7 months ago

All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
LXRX

GlobeNewswire

7 months ago

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
LXRX

GlobeNewswire

8 months ago

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
LXRX

Zacks

8 months ago

Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
LXRX

GlobeNewswire

8 months ago

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
LXRX

Zacks

8 months ago

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

LXRX

Associated Press Finance

8 months ago

Lexicon: Q4 Earnings Snapshot

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
LXRX

GlobeNewswire

8 months ago

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Share on Social Networks: